◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › AVTX

Avalo Therapeutics, Inc. - (AVTX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

NASDAQ · DATA UPDATED 2026-09-17

Avalo Therapeutics, Inc. - (AVTX) operates in the NASDAQ industry and is headquartered in Wayne, United States with about 33 employees. Its market capitalization is roughly $889 million. In the fiscal year ended 2025-12-31, AVTX reported $0M in revenue and ($78M) in net income.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States.

Interactive charts & full statements → Open the AVTX valuation workbench →

AVTX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$0M	$0M	$0M	$2M	$18M	$5M	$7M	$7M	$18M	$28M	$1M	—	—	—	$0M
Gross Profit	—	$0M	$1M	$1M	$15M	$4M	$6M	$7M	$11M	$27M	($7M)	$0M	($10M)	—	($8M)
Gross Margin %	—	100.0%	183.0%	33.3%	81.0%	72.4%	95.5%	108.4%	59.2%	97.7%	-614.6%	—	—	—	-10142.4%
Operating Income (EBIT)	($91M)	($73M)	($69M)	($27M)	($37M)	($82M)	($27M)	($16M)	($39M)	$14M	($16M)	($11M)	($17M)	($13M)	($10M)
Operating Margin %	-154844.1%	-123601.7%	-15535.6%	-1421.6%	-207.4%	-1521.6%	-402.3%	-239.1%	-214.5%	49.9%	-1394.6%	—	—	—	-12676.3%
Net Income	($100M)	($78M)	($35M)	($32M)	($42M)	($84M)	($64M)	($16M)	($40M)	$12M	($16M)	($10M)	($16M)	($13M)	($10M)
Net Margin %	-170055.9%	-132642.4%	-7965.8%	-1639.5%	-230.8%	-1563.1%	-947.9%	-238.1%	-218.6%	42.7%	-1428.5%	—	—	—	-12674.7%
EBITDA	($100M)	($78M)	($35M)	($23M)	($37M)	($80M)	($45M)	($14M)	($13M)	$14M	($16M)	($10M)	($17M)	($13M)	($10M)
Earnings Per Share (EPS)	$-2.27	$-5.84	$-3.26	$-113.58	$-1,062.65	$-2,331.41	$-2,489.12	$-809.74	$-3,317.28	$1,822.74	$-5,371.95	$-13,571.91	$-41.61	$-43.12	$-199.77
Shares Outstanding (M)	44M	13M	11M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AVTX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Profit	—	$0M	$0M	($10M)	($11M)	($6M)	$0M	$1M
Gross Margin %	—	—	100.0%	—	—	—	54.7%	386.8%
Operating Income (EBIT)	($32M)	($21M)	($20M)	($19M)	($19M)	($15M)	($13M)	($13M)
Operating Margin %	—	—	-33461.0%	—	—	—	-6932.8%	-5165.1%
Net Income	($36M)	($20M)	($14M)	($31M)	($21M)	($13M)	($35M)	$23M
Net Margin %	—	—	-23254.2%	—	—	—	-18405.7%	9251.8%
EBITDA	($36M)	($20M)	($14M)	($31M)	($21M)	($13M)	($35M)	$23M
Earnings Per Share (EPS)	$-0.83	$-0.98	$-0.74	$-2.19	$-1.92	$-1.25	$-3.37	$2.14
Shares Outstanding (M)	44M	20M	19M	14M	11M	11M	10M	11M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AVTX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cash from Operations (CFO)	($66M)	($51M)	($49M)	($31M)	($27M)	($71M)	($41M)	($19M)	($3M)	$13M	($15M)	($10M)	($16M)	($11M)	($9M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$1M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($66M)	($51M)	($49M)	($31M)	($27M)	($71M)	($41M)	($19M)	($4M)	$12M	($15M)	($10M)	($16M)	($12M)	($9M)
FCF Margin %	-112505.1%	-87216.9%	-11123.8%	-1602.8%	-148.7%	-1315.4%	-606.1%	-287.3%	-20.2%	44.9%	-1267.0%	—	—	—	-11238.1%
Dividends Paid	—	—	—	—	$15M	$33M	—	$1M	—	—	—	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AVTX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($18M)	($18M)	($14M)	($16M)	($11M)	($9M)	($15M)	($12M)
Free Cash Flow (FCF)	($18M)	($18M)	($14M)	($16M)	($11M)	($9M)	($15M)	($12M)
FCF Margin %	—	—	-24145.8%	—	—	—	-7835.4%	-4629.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AVTX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Assets	$491M	$116M	$151M	$21M	$33M	$80M	$44M	$36M	$70M	$43M	$6M	$22M	$12M	$5M	$10M
Cash & Cash Equivalents	$85M	$16M	$135M	$7M	$13M	$55M	$19M	$4M	$11M	$2M	$5M	$21M	$12M	$3M	$10M
Total Liabilities	$42M	$33M	$18M	$14M	$44M	$57M	$19M	$15M	$49M	$15M	$6M	$9M	$39M	$23M	$2M
Total Debt (Short + Long-Term)	$0M	$0M	$1M	$1M	$20M	$33M	$0M	$0M	$15M	$0M	$2M	$3M	$2M	$0M	$0M
Total Shareholders' Equity	$449M	$83M	$133M	$7M	($11M)	$23M	$25M	$21M	$21M	$28M	$0M	$13M	($26M)	($18M)	$8M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AVTX viewer.

Other Companies in Software & IT Services

MRCH · Merchants Trust Ord — £980 million
JFJ · JPMorgan Japanese Ord — £918 million
MUT · Murray Income Trust Ord — £906 million
TRY · TR Property Ord — £906 million
RERE · ATRenew Inc. American Depositary Shares (every three of which representing two Class A ordinary shares) — $868 million
PPET · Patria Private Equity Trust — £856 million
JEGI · JPMorgan European Growth & Income Ord — £846 million
ICGT · ICG Enterprise Trust Ord — £843 million

← AVTR All “A” companies AVUE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.